drugset / Trial / NCT04952493
Anlotinib or Penpulimab in Combination With RAI for DTC
Phase 2
Unknown
42 enrolled
Peking Union Medical College Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy and safety of anlotinib in combination with I-131 in locally advanced/metastatic differentiated thyroid cancer. Anlotinib may stop the growth of tumor cells and improve iodine uptake.
Timeline
- Start
- 2021-09-15
- Primary completion
- 2023-07-20
- Completion
- 2024-07-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | — | — |
| Subject | Penpulimab | Monoclonal antibody | — | — |
| Subject | Sodium Iodide I 131 | Unknown | — | — |